Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

Conditions

• Central Retinal Vein Occlusion
• Proliferative Diabetic Retinopathy

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Intravitreal Aflibercept Injection — DRUG
  Aflibercept administered to the eye intravitreally either every month or every other month.

Study Details

The purpose of this study is to look at how effective, safe, and well tolerated Intravitreal Aflibercept Injection is in subjects with Central Retinal Vein Occlusion (CRVO) or Proliferative Diabetic Retinopathy (PDR).

Key Dates

Start date

Nov 30, 2012

Status verified

May 2015

Primary completion

Oct 31, 2014

Completion

Oct 31, 2014

Study Design

Enrollment

24 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Every Month Treatment
  Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the 12 month duration of the study.
• Experimental: Every Month, then Every Other Month
  Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the first 6 months, then every other month for the next 6 months. Retreatment criteria will allow for patients to be treated every month in the second 6 months if needed.

Primary Outcome Measure

Mean Change in Capillary Non-Perfusion [ Time Frame: 12 months ]

Locations (1)

Find similar trials in Boston, MA